BridgeBio Oncology Therapeutics Inc.
BBOTHealthcare|Biotechnology|US
$2.04
-0.13 (-5.99%)
DCF Value
$11.88
Tangible Book / Share
$4036.18
Cash / Share
$2819.48
Financials
Financial Snapshot
Market Cap
$163.6M
Enterprise Value
$112.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$182.1M
Cash & Investments
$225.7M
Net Cash
$223.2M
Free Cash Flow (TTM)
-$193.8M
Operating CF (TTM)
-$193.1M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$225.7M
Quarterly Burn
$48.3M
Monthly Burn
$16.1M
Est. Runway
~4.7 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $0.00 | $0.00 | $1.7M | $425.5M | $225.7M | |
| Operating Cash Flow | $0.00 | $0.00 | -$52.1M | -$763.8K | -$113.9M | -$193.1M | |
| Free Cash Flow | $0.00 | $0.00 | -$52.5M | -$763.8K | -$114.5M | -$193.8M | |
| Capital Expenditure | $0.00 | $0.00 | -$414.0K | $0.00 | -$606.0K | -$677.0K | |
| Financing Cash Flow | $0.00 | $0.00 | $55.1M | $186.5M | $383.4M | $383.7M |
R&D Spending
R&D (TTM)
$162.2M
R&D Intensity
—
R&D Growth vs Prior
+33.8%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $56.3M | $73.1M | $121.2M | $162.2M | |
| SG&A | $43.4K | $3.5K | $8.5M | $7.8M | $24.6M | $36.8M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $186.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$186.0K | |
| R&D | $0.00 | $0.00 | $56.3M | $73.1M | $121.2M | $162.2M | |
| SG&A | $43.4K | $3.5K | $8.5M | $7.8M | $24.6M | $36.8M | |
| Operating Income | -$43.4K | -$3.5K | -$64.8M | -$80.9M | -$145.8M | -$199.0M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$43.4K | -$3.5K | -$64.7M | -$74.3M | -$134.0M | -$182.1M | |
| Net Income | -$43.4K | -$3.5K | -$64.7M | -$74.3M | -$134.0M | -$182.1M | |
| EPS (Diluted) | -0.00 | -0.00 | -3.16 | -5756.41 | -4.30 | -709.70 | |
| EBITDA | -$43.4K | $0.00 | -$64.7M | -$80.7M | -$145.2M | -$194.5M | |
| Shares Out. (M) | 20.48 | 20.48 | 20.48 | 0.01 | 31.14 | 0.08 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $0.00 | $0.00 | $1.7M | $373.7M | $54.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $51.8M | $171.6M | |
| Total Current Assets | $0.00 | $0.00 | $0.00 | $1.9M | $425.5M | $242.4M | |
| Total Assets | $144.3K | $144.6K | $332.9K | $194.4M | $448.4M | $376.7M | |
| Total Current Liabilities | $162.6K | $166.5K | $396.5K | $187.5K | $35.0M | $51.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $2.2M | $2.0M | |
| Total Liabilities | $162.6K | $166.5K | $396.5K | $5.7M | $37.3M | $53.6M | |
| Stockholders' Equity | -$18.4K | -$21.9K | -$63.6K | $188.7M | $411.1M | $323.1M | |
| Retained Earnings | -$43.4K | -$46.9K | -$88.6K | -$3.7M | -$356.6M | -$455.1M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $0.00 | -$52.1M | -$763.8K | -$113.9M | -$193.1M | |
| Capital Expenditure | $0.00 | $0.00 | -$414.0K | $0.00 | -$606.0K | -$677.0K | |
| Free Cash Flow | $0.00 | $0.00 | -$52.5M | -$763.8K | -$114.5M | -$193.8M | |
| Investing Cash Flow | $0.00 | $0.00 | -$2.8M | -$184.0M | $73.3M | -$166.3M | |
| Financing Cash Flow | $0.00 | $0.00 | $55.1M | $186.5M | $383.4M | $383.7M | |
| Issuance of Stock | $0.00 | $0.00 | $3.6M | $187.3M | $395.7M | $22.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$209.9K | $0.00 | $373.5M | |
| Stock Based Comp. | $0.00 | $0.00 | $16.5M | $271.6K | $5.9M | $10.2M | |
| Net Change in Cash | $0.00 | $0.00 | $225.0K | $1.7M | $342.8M | $53.4M |
Dilution Tracker
Shares outstanding grew 52.0% over 5 years — significant dilution
Shares Outstanding
80M
5-Year Share Growth
+52.0%
Stock Issuance (TTM)
$22.7M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 20.48 | 20.48 | 20.48 | 0.01 | 31.14 | 0.08 | |
| Change vs Prior % | — | 0.0% | 0.0% | -99.9% | 241276.2% | -99.7% | |
| Stock Issuance | $0.00 | $0.00 | $3.6M | $187.3M | $395.7M | $22.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $16.5M | $271.6K | $5.9M | $10.2M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 236.2% | 16.1% | 101777.6% | -39.4% | -32.6% | -46.9% | |
| ROA % | -30.1% | -2.4% | -19435.3% | -38.2% | -29.9% | -48.3% | |
| ROIC % | -233.1% | -16.6% | -992506.9% | -41.6% | -35.2% | -61.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 91.9% | -1839985.2% | -24.8% | -80.3% | |
| Net Income | 0.0% | 91.9% | -1837939.8% | -14.8% | -80.5% | |
| EPS (Diluted) | 0.0% | 90.5% | -1579900.0% | -182064.9% | 99.9% | |
| Operating Cash Flow | 0.0% | 0.0% | 0.0% | 98.5% | -14811.1% | |
| Free Cash Flow | 0.0% | 0.0% | 0.0% | 98.5% | -14890.4% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 29.9% | 65.8% | |
| SG&A Expense | 0.0% | -91.9% | 240951.1% | -8.6% | 217.4% | |
| Total Assets | 0.0% | 0.2% | 130.3% | 58304.2% | 130.6% | |
| Book Value / Share | 0.0% | -19.2% | -190.6% | 471313927.4% | -99.9% | |
| Debt | 0.0% | 16.6% | 62.6% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -99.9% | 241276.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.00
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$11.88
Tangible Book / Share
$4036.18
Net Current Assets / Share
$2.35
Graham Net-Net
$2150.01
Cash / Share
$2819.48
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -4852.38 | -59301.75 | -5095.00 | -0.00 | -2.91 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -11371.26 | -9541.63 | -3283.71 | 0.00 | 0.95 | 0.00 | |
| EV/EBITDA | -4815.35 | 0.00 | -3.23 | 0.02 | -0.13 | -0.58 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-0.96
Distress
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $29.1M | $0.00 |
| Net Income | -$80.4M | -$78.2M | -$78.5M |
| EPS | $-2.59 | $-2.52 | $-2.47 |
| # Analysts (EPS) | 7 | 7 | 10 |